Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 14/20 | 0.62 |
| ▸ | ROS1 | P08922 | 14/20 | 0.62 |
| ▸ | FLT3 | P36888 | 14/20 | 0.62 |
| ▸ | EML4 | Q9HC35 | 9/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25562695 | 0.93 | RET (0.61) | RETROS1FLT3EML4ALK | |
| SCHEMBL25562810 | 0.92 | RET (0.62) | RETROS1FLT3EML4ALK | |
| SCHEMBL25562824 | 0.91 | RET (0.61) | RETROS1FLT3EML4ALK | |
| SCHEMBL25561911 | 0.89 | RET (0.66) | RETROS1FLT3EML4ALK | |
| SCHEMBL25562818 | 0.89 | RET (0.66) | RETROS1FLT3EML4ALK | |
| SCHEMBL25561917 | 0.89 | RET (0.70) | RETROS1FLT3EML4ALK | |
| SCHEMBL25562815 | 0.89 | RET (0.67) | RETROS1FLT3EML4ALK | |
| SCHEMBL25252177 | 0.88 | RET (0.59) | RETROS1FLT3EML4ALK | |
| SCHEMBL25561881 | 0.88 | RET (0.48) | RETROS1FLT3EML4ALK | |
| SCHEMBL25562897 | 0.88 | RET (0.62) | RETROS1FLT3EML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | EGFR, ERBB2, WEE1 | RET 22/4885ROS1 31/4885FLT3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.